> AMGN stock

Stay informed on AMGN stock with the most important news summaries, insider trading, valuation highlights and analyst recommendations

AMGN stock news: A summarized overview for you, just the bottom line of the most recent news items!

Last Updated: May 09, 2024

Mizuho Ups Amgen's Price Target to $235
- 🚀 Mizuho's new love for Amgen has the biotech scene buzzing! They've cranked up the target price to a cool $235. Looks like health care's getting a shot in the arm - might be time for savvy investors to tune in.
- 💥 That’s right, folks! A whopping $30 leap from their last prophecy. This isn't just a nod of approval; it's a full-blown standing ovation for Amgen’s future shine. Bet your bottom dollar, analysts are seeing glitter in those earnings reports.
- 💡 Drooling over Amgen yet? This kind of analyst adoration tends to set the stage for a price pep rally. If you’ve got an eye for action, this uptick in attention could mean lively trading days ahead with some tasty potential for portfolio plumping.
Discover 3 Essential Dividend Stocks Including Amgen
- Diving deep into the dividend treasure trove, seasoned and savvy investors, listen up! Amgen, Merck, and AbbVie aren't just your ordinary picks. They're the cream of the crop with their alluring yields that scream 'buy me!' and 'hold me tight!'. With fundamentals as solid as a rock and growth prospects brighter than the North Star, these stocks beckon for a spot in your portfolio.
- For those who prefer the slow dance over the quickstep in the unpredictable tango of the stock market, here's your rhythm. These three musketeers offer a sanctuary of diversification and income, making them the perfect partners for the risk-averse dancers among us. Steady cash flow? Check. A buffer against market tantrums? Double check. In the quest for long-term returns, Amgen, Merck, and AbbVie emerge as knights in shining armor.
- Imagine a spotlight intensifying on our trio - Amgen, Merck, and AbbVie. As word of their appeal spreads, we could witness a surge of suitors lining up, checkbooks in hand. This increased demand might not just bolster their prices but can also prop up their stance in the market arena. A win-win in the making, wouldn’t you agree? So, if you're thinking of jazzing up your portfolio, now might be the perfect time to make your move.
What Investors Should Know About Trending Amgen Stock
- Amgen took a nosedive on Friday, feeling the heat after their fourth-quarter earnings missed the mark. The villain? Unfriendly foreign exchange rates that decided to crash the party. In short, it's a bit of a bumpy ride in their financial narrative.
- Despite the stumble, it's not all doom and gloom. Amgen's got its armor in the form of solid core earnings, thanks largely to its knights in shining molecules - rentibodies and cardiovascular drugs. These segments flexed their muscles, showing that even on rainy days, some lights still shine bright.
- After a spirited sprint that saw the stock climb a hearty 21% from its November lows, Amgen might just be hitting the pause button for a breather. The market's abuzz with whispers of a cool-down period. For investors, it's a moment to watch closely, perhaps with an espresso in hand, as they ponder Amgen's next move in the biotech chess game.

Real-time price chart of AMGN stock

Stay up-to-date with the latest performance of Amgen, (AMGN) through our real-time stock chart, providing live insights into its market movements

AMGN stock valuation - less noise, just the highlights

Despite broader market fluctuations, AMGN shows a steady price change over the year with a 2.33% increase, combined with a market cap of $164.85B, underscoring its financial stability and appeal for long-term investment within Amgen valuation strategies.
AMGN's consistent EPS growth, with a forecast of 6.11% next year and an average EPS growth of 5.72% for the next 5 years, underpins a solid growth perspective for investors and traders, enhancing the attractiveness of AMGN valuation.
The forward P/E ratio of 14.84 for AMGN indicates a potential undervaluation compared to the current P/E ratio of 43.94, signaling an attractive entry point for investors focused on Amgen valuation.

Stay informed with the latest AMGN stock analyst recommendations:

Recent upgrades from reputable analysts such as William Blair and Barclays indicate a positive shift in sentiment towards AMGN stock, with William Blair moving from 'Market Perform' to 'Outperform' and Barclays upgrading from 'Underweight' to 'Equal Weight'. This suggests a growing confidence in Amgen's market position and future prospects, providing a solid reason for investors and traders to consider AMGN positively in their portfolios.
The changes in price targets from multiple analysts highlight the potential for significant upside. For instance, Barclays increased their price target from $230 to $300, and Daiwa Securities from $264 to $320, indicating that experts foresee a higher valuation for Amgen, which can be a lucrative indicator for potential investors seeking growth opportunities in their investment approach.
Amgen has received consistent attention from analysts across the board, with upgrades and positive adjustments dominating the landscape. The switch from 'Hold' to 'Buy' by Truist and an upgrade from 'Market Perform' to 'Outperform' by BMO Capital Markets, accompanied by substantial price target revisions, underscore AMGN's strong standing in the biotech sector. For traders and investors, staying abreast of these shifts can guide more informed decisions, leveraging the aggregated insights from these professional analyses.

Stay updated on AMGN stock insider trading with these key points:

Heavy insider sales could indicate insiders' belief of AMGN's stock being overvalued, but purchases, especially large ones by top executives or significant shareholders, imply confidence in the company's future. For instance, a significant purchase by AMGEN INC as a 10% owner suggests strong internal optimism about the stock, potentially a buy signal to investors.
The involvement of key roles such as SVP & CCO (Senior Vice President & Chief Compliance Officer), EVP (Executive Vice President), General Counsel & Secretary, and EVP of Global Commercial Ops in recent trades provides crucial signals. Sales by these insiders could indicate their personal financial management but repeated or heavy sales might be seen as a cautious sign for investors.
The timing and frequency of insider trades, such as the concentrated sales within a relatively short period, can offer hints about the internal sentiment towards the stock's valuation. Consistent insider buying, particularly at increasing share prices, could signify undervaluation or potential growth, serving as a trigger for investors to consider buying AMGN stock.

AMGN technical analysis

Unlock insights to make smarter investment decisions with this real-time technical analysis tool. Dive in to see the latest buy and sell signals tailored for today's dynamic market. Get the market's inside scoop in a flash! Peek at our fun and user-friendly ratings to see what it is whispering about your AMGN stock, within various timeframes.

Join the Discussion: What's your outlook on AMGN stock's performance?

Are you considering investing in AMGN or have you already done so? Share your thoughts below with the investor and trader community at ForexLive.com, share your angles, analysis, predictions, or questions about AMGN in the comments below! Your input matters to us.

Please note that this content regarding AMGN stock is for informational purposes only, includes opinions and not recommendations, and is not intended as investment or trading advice; invest in and/or trade AMGN at your own risk only.

Explore additional stocks:

Discover Ameriprise Financial stock with its new summaries, insider trading, valuation highlights and analyst recommendations

Contact us
Newsletter

!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}